The life science tools and diagnostics sector logged a trio of billion-plus dollar transactions in the first half of 2026, highlighting consolidation across research, lab workflows and advanced diagnostics. Merck KGaA announced plans to acquire Bio-Techne for about $11.3 billion, while Astorg proposed to buy Thermo Fisher Scientific’s microbiology business for about $1.08 billion and Roche agreed to acquire digital pathology company PathAI for roughly $1.05 billion. The report said the deals did not match the peak pace of late 2025, but outpaced the year-ago period and contributed to a wider wave of biopharma dealmaking, including other sub-$1 billion acquisitions. In parallel, the article noted IPO activity remains slow, with fewer public offerings and a market that still appears more favorable for diagnostics and tools compared with broader biotech fundraising.